CA2602635C - Method of altering the binding specificity of proteins by oxidation-reduction reactions - Google Patents

Method of altering the binding specificity of proteins by oxidation-reduction reactions Download PDF

Info

Publication number
CA2602635C
CA2602635C CA2602635A CA2602635A CA2602635C CA 2602635 C CA2602635 C CA 2602635C CA 2602635 A CA2602635 A CA 2602635A CA 2602635 A CA2602635 A CA 2602635A CA 2602635 C CA2602635 C CA 2602635C
Authority
CA
Canada
Prior art keywords
binding specificity
altering
proteins
oxidation
reduction reactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2602635A
Other languages
English (en)
French (fr)
Other versions
CA2602635A1 (en
Inventor
John A. Mcintyre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redox Reactive Reagents LLC
Original Assignee
Redox Reactive Reagents LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redox Reactive Reagents LLC filed Critical Redox Reactive Reagents LLC
Publication of CA2602635A1 publication Critical patent/CA2602635A1/en
Application granted granted Critical
Publication of CA2602635C publication Critical patent/CA2602635C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2602635A 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions Expired - Fee Related CA2602635C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/108,826 US9557325B2 (en) 2003-06-09 2005-04-19 Method of altering the binding specificity of proteins by oxidation-reduction reactions
US11/108,826 2005-04-19
PCT/US2006/012802 WO2006113139A2 (en) 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions

Publications (2)

Publication Number Publication Date
CA2602635A1 CA2602635A1 (en) 2006-10-26
CA2602635C true CA2602635C (en) 2014-12-23

Family

ID=37115646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2602635A Expired - Fee Related CA2602635C (en) 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions

Country Status (9)

Country Link
US (1) US9557325B2 (https=)
EP (1) EP1871171A4 (https=)
JP (1) JP2008536920A (https=)
CN (1) CN101262774A (https=)
AU (1) AU2006236928B2 (https=)
BR (1) BRPI0608373A2 (https=)
CA (1) CA2602635C (https=)
MX (1) MX2007013171A (https=)
WO (1) WO2006113139A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
AU2004248155B2 (en) * 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US8372387B2 (en) * 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US7989596B2 (en) * 2007-09-19 2011-08-02 Redox-Reactive Reagents Llc Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
EP2326952B1 (en) * 2008-09-04 2015-07-29 Redox-Reactive Reagents, Llc Method for diagnosing, monitoring, and/or staging alzheimer's disease
US20120107841A1 (en) * 2010-07-19 2012-05-03 Mcintyre John A Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
CN102818896B (zh) * 2011-06-09 2014-12-17 北京华大蛋白质研发中心有限公司 一种基于特异抗体的硝基化修饰位点的检测方法及特异识别scot硝基化位点的抗体
EP2836845B1 (en) 2012-04-13 2018-05-09 DiabetOmics, Inc. Maternal biomarkers for gestational diabetes
WO2016081413A1 (en) * 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
ES2748117T3 (es) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnóstico de una nueva enfermedad autoinmune
CN113490539A (zh) * 2019-05-29 2021-10-08 松下知识产权经营株式会社 检测方法和检测装置
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
CN118526489B (zh) * 2024-05-24 2025-04-01 南通大学 一种脱镁叶绿酸乙酯的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703001A (en) 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
US5061790A (en) 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
AU703814B2 (en) 1995-12-04 1999-04-01 Wyeth Antioxidant
US5939394A (en) 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Also Published As

Publication number Publication date
CA2602635A1 (en) 2006-10-26
MX2007013171A (es) 2008-01-18
JP2008536920A (ja) 2008-09-11
CN101262774A (zh) 2008-09-10
AU2006236928A1 (en) 2006-10-26
AU2006236928B2 (en) 2011-06-23
US9557325B2 (en) 2017-01-31
EP1871171A4 (en) 2015-08-19
BRPI0608373A2 (pt) 2010-11-16
WO2006113139A3 (en) 2007-08-23
EP1871171A2 (en) 2008-01-02
US20050260681A1 (en) 2005-11-24
WO2006113139A2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
EP1631314A4 (en) METHOD FOR MODIFYING BINDING SPECIFICITY OF PLASMIC PROTEINS USING OXIDATION-REDUCTION REACTIONS
CA2602635C (en) Method of altering the binding specificity of proteins by oxidation-reduction reactions
ATE404695T1 (de) Einfache katalytische dna-biosensoren für ionen auf grundlage von farbveränderungen
DE60330841D1 (de) Überexpression von extremozymgenen in pseudomonas und nahe verwandte bakterien
WO2008092041A3 (en) Optical biosensors
WO2008055257A3 (en) Cartridge for conducting diagnostic assays
DE602004001227D1 (de) Nukleinsäure-biosensor
ATE431405T1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
WO2005030984A3 (en) Method for small volume nucleic acid synthesis
BRPI0001536B8 (https=)
WO2007086879A3 (en) Method of expressing proteins with disulfide bridges
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
ATE524482T1 (de) Ionische flüssigkeiten mit niedriger viskosität
MX2007012486A (es) Ensayos de investigacion sobre estilbazio.
WO2009076651A3 (en) Methods for identifying compounds that modulate lisch-like protein or c1orf32 protein activity and methods of use
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
WO2002044378A3 (en) Wnt signalling assay, methods and uses thereof
WO2004010143A3 (en) Electrochemical lateral flow and flow-through devices
ATE540966T1 (de) Von phenoxazinon abgeleitete neue enzymsubstrate und deren verwendung als entwickler bei der detektion von mikroorganismen mit peptidaseaktivität
EP1918367A3 (en) Desaturase Enzymes
WO2009116984A3 (en) Highly thermostable fluorescent proteins
GB0509611D0 (en) Method and device for imaging a sample
WO2005023422A3 (de) Herstellung und verwendung von ionischen flüssigkeiten mit thiocyanat als anion
WO2001030986A3 (en) Human pif1 dna helicase and uses thereof
WO2005024061A3 (en) Compounds and methods for modulation of dna replication

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210406